Skip to main content
S&P 5007,743.41+0.51%DOW51,828.62+0.93%NASDAQ27,068.72+0.48%BTC$83,896.00-0.86%ETH$2,687.00-0.12%GOLD$4,320.50+0.52%OIL$92.44-2.29%
Smart Investors Daily
Biodexa Pharmaceuticals Plc logo

NASDAQ · BDRX

Biodexa Pharmaceuticals Plc

Healthcare · Biotechnology

$0.68

Up+$0.00 (+0.15%)

Updated Sep 26, 2026, 1:28 AM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
4.12M
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.60 – $11.88
Volume
127.73K
Avg. volume
695.79K

Price performance

BDRX price history

1M range · 19 trading sessions · Daily adjusted prices

BDRX closed at $0.68 after 19 trading sessions, down 22.24% for the selected period.

Last close
$0.68
Period change
-22.24%
Period low
$0.66
Period high
$1.33
Daily close
View OHLC price history
BDRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 24, 2026$0.67$0.6935$0.658$0.675127.73K
Sep 23, 2026$0.6827$0.73$0.655$0.6894374.48K
Sep 22, 2026$0.67$0.69$0.61$0.681745.58K
Sep 21, 2026$0.7401$0.7419$0.62$0.6799629.25K
Sep 18, 2026$0.7795$0.8325$0.71$0.73585.12K
Sep 17, 2026$0.8701$0.9459$0.72$0.79991.55M
Sep 16, 2026$1.23$1.27$0.85$0.963.43M
Sep 15, 2026$1.29$1.43$1.13$1.3354.69M
Sep 14, 2026$1.29$1.46$1.10$1.126.16M
Sep 11, 2026$0.88$1.5499$0.8342$1.30142.44M
Sep 10, 2026$0.7998$0.845$0.61$0.6601202.08K
Sep 9, 2026$0.8441$0.8441$0.79$0.8122101.77K
Sep 8, 2026$0.82$0.8999$0.82$0.830895.25K
Sep 4, 2026$0.7838$0.86$0.7731$0.848105.07K
Sep 3, 2026$0.771$0.7988$0.7623$0.798499.61K
Sep 2, 2026$0.758$0.80$0.7553$0.784958.77K
Sep 1, 2026$0.79$0.81$0.7802$0.780882.69K
Aug 31, 2026$0.8576$0.8576$0.78$0.8117114.31K
Aug 28, 2026$0.87$0.88$0.8303$0.8681110.16K

Latest BDRX news

The latest Smart Investors Daily articles mentioning BDRX.

Stock researchCompany · Overview

BDRX research

Overview

Company profile and research snapshot.

Company profile

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$183.60
Implied upside
—
Analysts
7
BDRX recent ratings
DateFirmRatingTarget
Feb 8, 2024Ladenburg ThalmannBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 15, 2026

Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds

Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds September 15, 2026 Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 2,2

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By